A Study of LY3439539 in Participants With Alzheimer's Disease
← catalyst calendarNCT07598370 · readout ≤ 377 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Basic science
Enrollment
30estimated
Sites
8
Countries
Australia, New Zealand, Singapore +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-21 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Alzheimer Disease
Intervention
- Drug: LY3439539
Primary outcome
what the primary-completion date above is the date OFChange from Baseline in Cerebrospinal Fluid (CSF) Neurofilament Light Chain (NfL)
measured Baseline through end of the Follow-up Period (Week 24)
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed